Movado Unveils “Always in Motion. Since 1881.” Campaign
8.9.2025 13:30:00 CEST | Business Wire | Press Release
Movado (NYSE: MOV) launches the second chapter of its campaign, Always in Motion. Since 1881. The campaign reunites the Movado Icons—Ludacris, Jessica Alba, Christian McCaffrey, Julianne Moore, and Tyrese Haliburton—visionaries who continue to set the pace in culture and in their crafts.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908571091/en/
photographer Stuart Winecoff
“In our second year, we continue to deepen our storytelling by celebrating Movado’s heritage and Swiss craftsmanship,” said Margot Grinberg, President of Movado. “Building on last year’s campaign, we remain true to our DNA with a concept inspired by the meaning of Movado ‘always in motion’—in Esperanto. This campaign showcases the design and intricate details of our watches, capturing each Icon through a more intimate lens. Paired with a piece from our latest collection, they reflect how our Icons move, create, live and how Movado is included in these moments.”
Directed and photographed by Stuart Winecoff, the cinematic films and portraits follow Ludacris, Alba, McCaffrey, and Moore through John Lautner’s Harvey House in Los Angeles. The landmark’s midcentury lines, sun-washed interiors, and shifting perspectives capture light, motion, and the Icons’ movements in the moment—and how Movado watches move with them.
Fresh off leading his team to the NBA Finals, Haliburton was photographed in Indianapolis by Jennifer Livingston inside a midcentury modern residence designed by renowned architect Evans Woollen III. Haliburton’s imagery reflects the same architectural dialogue of light, space, and form seen in Los Angeles.
Each Icon wears a watch that reflects their individuality and craft. Ludacris embodies rhythm and momentum in the BOLD Quest, a 1970s archival-inspired design balancing timeless geometry with modern edge. Jessica Alba and Julianne Moore move with intention, present in the moment, with the Museum Bangle, evoking refined elegance rooted in Movado’s history. Christian McCaffrey channels focus and precision with the Museum Imperiale, uniting elegant design and sport-driven performance. Tyrese Haliburton embodies motion, heritage, and modern vision, pairing his dynamic energy with the Heritage 1917 collection, a reimagining of Movado’s first square watch, introduced in 1917 with Art Deco lines, stylized Arabic numerals, and a distinctive silhouette. These new collections represent Movado’s philosophy of design in motion. Each piece captures Movado’s enduring vision—modern, minimal, and always in motion—celebrating how today’s Icons shape the present while carrying forward a legacy of innovation.
The campaign is live globally across digital and social platforms, select retail locations, and at movado.com, inviting audiences to see the films and explore the collections in full.
CREDITS
- Creative Director: Robert Lussier, The Style Council, Paris
- Production Company: JN Productions
- Social Director / Photographer: Mac Shoop
- Los Angeles - stills and motion portraits: Stephen Kidd
- Stylist Los Angeles: George Cortina
- Stylist Indiana: Olivier Rogers
- Set Designer Los Angeles: Christine Irwin
About Movado
Since 1881, Movado has always been in motion and always moving forward. Its commitment to modern design and innovation has made Movado one of the world’s premier watchmakers, with a proud 144-year heritage of Swiss craftsmanship, design, and excellence. Expertly combining artistry, innovation, and technology, Movado has earned over 100 patents and has timepieces on display in 20 museums worldwide.
About Movado Group
Movado Group, Inc. designs, sources, and globally distributes and sells MOVADO®, MVMT®, OLIVIA BURTON®, EBEL®, CONCORD®, CALVIN KLEIN®, COACH®, TOMMY HILFIGER®, HUGO BOSS®, and LACOSTE® watches and, to a lesser extent, jewelry and other accessories, and operates Movado Company Stores in the United States and Canada.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250908571091/en/
Contacts
ICR, Inc.
Allison Malkin
203-682-8200
Heather Cohen Sugarman
Vice President, Public Relations
Movado Group
hcohen@movadogroup.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom